Decreased FOXO3a expression is reported to be correlated with the progression, occurrence, and poor prognosis in breast cancer [16], gastric cancer [17], ovarian cancer [18], nasopharyngeal carcinoma [19], and hepatocellular carcinoma [20]. This evidence concerns the gene FOXO3 and gastric cancer.